This Fortress Biotech Insider Increased Their Holding By 26% Last Year
Looking at Fortress Biotech, Inc.'s ( NASDAQ:FBIO ) insider transactions over the last year, we can see that insiders...
| Ticker |
FBIO
|
| CIK | 0001429260 |
| SIC | 2834 |
| Sector | Manufacturing |
| Industry Category | Pharmaceutical Products |
| Industry Group | Pharmaceutical Preparations |
| Address | 1111 KANE CONCOURSE, SUITE 301, BAY HARBOR ISLANDS, FL, 33154 |
| Website | fortressbiotech.com |
| Phone | 781-652-4500 |
| CEO | Lindsay A. Rosenwald |
| Employees | 170 |
Our team will help you customize a package that meets the needs of your business.
Request a Consultation|
Standardized FinancialsdocsIntrinio provides professional-grade historical financial data. This data is standardized, cleansed and verified to ensure the highest quality data sourced directly from the XBRL financial statements. The primary purpose of standardized financials are to facilitate comparability across a single company’s fundamentals and across all companies fundamentals. For example, it is possible to compare total revenues between two companies as of a certain point in time, or within a single company across multiple time periods. This is not possible using the as reported financial statements because of the inherent complexity of reporting standards. Below is a preview of several data points from each financial statement, as well as a sample of our many calculated metrics: |
|||||||||||||||||||||
|
Income Statement
|
Balance Sheet
|
||||||||||||||||||||
|
Cash Flow Statement
|
Calculations
|
||||||||||||||||||||
|
Latest NewsdocsIntrinio provides up-to-date news articles on every US company from various sources. Here are several examples: |
This Fortress Biotech Insider Increased Their Holding By 26% Last YearLooking at Fortress Biotech, Inc.'s ( NASDAQ:FBIO ) insider transactions over the last year, we can see that insiders... Journey Medical Corporation Appoints Ramsey Alloush as Chief Operating OfficerSCOTTSDALE, Ariz., April 01, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ: DERM) (“Journey Medical” or the “Company”), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of U.S. Food and Drug Administration (“FDA”) approved prescription pharmaceutical products for the treatment of dermatological conditions, is pleased to announce the promotion of Ramsey Alloush, currently General Counsel, to the position of Chief Operating Officer (“COO” Fortress Biotech (FBIO) Reports Q4 Loss, Lags Revenue EstimatesFortress Biotech (FBIO) delivered earnings and revenue surprises of 67.09% and 12.58%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock? Fortress Biotech Reports 2024 Financial Results and Recent Corporate HighlightsEmrosi™ approved by FDA for the treatment of inflammatory lesions of rosacea in adults, with commercial launch underway; initial distribution ongoing and first prescriptions filled Fortress subsidiary Checkpoint Therapeutics to be acquired by Sun Pharma; Checkpoint’s lead product, UNLOXCYT™, approved by FDA for the treatment of metastatic or locally advanced cutaneous squamous cell carcinoma FDA accepted New Drug Application filing for priority review for CUTX-101 to treat Menkes disease; PDUFA Checkpoint Therapeutics Reports Full-Year 2024 Financial Results and Recent Corporate UpdatesUNLOXCYT™ (cosibelimab-ipdl) approved by U.S. FDA as first and only anti-PD-L1 treatment for advanced cutaneous squamous cell carcinomaWALTHAM, Mass., March 28, 2025 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a commercial-stage immunotherapy and targeted oncology company, today announced financial results for the fiscal year ended December 31, 2024, and recent corporate updates. Recent Corporate Updates: In March 2025, Checkpoint announced that it entered in |